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Objective: To assess the association of dual antiplatelet therapy (DAPT) use and long-term clinical outcomes in patients undergoing primary 
stenting for ST-segment elevation myocardial infarction (STEMI).
Methods: HORIZONS-AMI was a prospective, randomized trial of paclitaxel-eluting stents (PES) vs. bare metal stents (BMS) in 3,006 patients 
undergoing primary PCI for STEMI. Landmark analysis was performed in 2,581 patients who remained free from death, myocardial infarction (MI), 
revascularization, stent thrombosis (ST) or major bleeding at 12-month follow-up, stratified according to DAPT usage at this time. Secondary 
analyses were performed according to randomized stent type. The primary endpoints were assessed at 36-month follow-up and included the 
composite outcome measure of major adverse cardiovascular events (MACE; death, MI, ischemic-driven target-lesion revascularization (TLR), ST or 
stroke) and net adverse clinical events (NACE; major bleeding or MACE) as well as the individual components of the composite endpoints.
Results: At 12 months 1,781 event-free patients (69%) were still taking DAPT (‘on DAPT’) and 800 event-free patients (31%) had discontinued 
DAPT (‘off DAPT’). In the pooled analysis, at 36 months there were no significant differences in outcomes between the ‘on DAPT’ and ‘off DAPT’ 
groups with regards to rates of death, TLR, stroke, ST and major bleeding as well the combined endpoints MACE and NACE. However, the rate of MI 
at 36 months was significantly higher in the ‘off DAPT’ group (2.8% on vs. 4.4% off, p=0.04). Among patients receiving PES, the ‘on DAPT’ group had 
significantly lower 1-3 year rates of MI (2.6% on DAPT vs. 4.8% off DAPT, p=0.01) and ST (1.2% on DAPT vs. 2.5% off DAPT, p=0.046). Among patients 
receiving BMS there were no significant differences in outcomes between the ‘on DAPT’ or ‘off DAPT’ groups.
Conclusions: Continuing DAPT usage after 12 months in event-free patients after primary PCI for STEMI treated with PES may reduce subsequent 
rates of MI and ST, warranting definitive randomized trials for this application. 
